This website is intended for healthcare professionals only.

Hospital Healthcare Europe
Hospital Pharmacy Europe     Newsletter    Login            

Empagliflozin recommended by NICE as add-on to standard care in CKD

The National Institute for Health and Care Excellence (NICE) has recommended that empagliflozin can be used as an option for treating chronic kidney disease (CKD) in adults under some circumstances.

It has to be prescribed as an add-on to standard care including the highest tolerated dose of angiotensin-converting-enzyme inhibitor or angiotensin-receptor blocker unless contraindicated, a Technology Appraisal has stated.

Under the recommendations, patients with CKD must also have an estimated glomerular filtration rate of:

  • 20 ml/min/1.73 m2 to less than 45 ml/min/1.73 m2 or
  • 45 ml/min/1.73 m2 to 90 ml/min/1.73 m2 and either a urine albumin-to-creatinine ratio of 22.6 mg/mmol or more, or type 2 diabetes.

Clinicians in both primary and secondary care should make prescribing decisions based on cost of suitable treatments including dapagliflozin after discussing the pros and cons with the patient, NICE said.

The committee noted that some patients already take dapagliflozin as an add-on to standard care and empagliflozin would be used in a similar way but with a potentially broader population.

Evidence from the EMPA-KIDNEY trial suggests that empagliflozin plus standard care is more effective than standard care alone for CKD but there were limits on who was included in the studies, NICE said.

Article continues below this sponsored advert
Cogora InRead Image
Explore the latest advances in respiratory care at events delivered by renowned experts from CofE
Advertisement

There are also no trials directly comparing empagliflozin plus dapagliflozin but it is likely that effectiveness and safety is similar, the committee said.

It was acknowledged that CKD can progress more quickly in some ethnic minority groups in people under 55 with type 2 diabetes but this could not be considered in the decision making, the committee noted.

The SGLT2 inhibitor is already recommended by NICE for the treatment of adult patients with type 2 diabetes and adult patients with heart failure with reduced ejection fraction.

NICE’s decision to include empagliflozin as an option in some patients with CKD means it must be made available within three months.

In papers published by the NICE committee, it notes that the use of SGLT2 inhibitors is not yet well established in clinical practice and there is ‘scope to expand the use of this drug class in this indication to slow CKD disease progression’.

Empagliflozin was approved by the European Medicines Agency for the treatment of adult patients with CKD in July 2023.

A version of this article was originally published by our sister publication Pulse.

x